NRIX: Nurix Therapeutics Inc. Common stock Stocks News on November 17, 2025

Nurix Therapeutics to Participate in Upcoming Investor Conferences

NRIX

GlobeNewswire

18 days ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

NRIX

MT Newswires

21 days ago

Nurix Therapeutics Closes $250 Million Underwritten Public Stock Offering

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

NRIX

GlobeNewswire

21 days ago

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NRIX

GlobeNewswire

5 months ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NRIX

MT Newswires

5 months ago

RBC Raises Price Target on Nurix Therapeutics to $28 From $27, Keeps Outperform, Speculative Risk

$Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)$

NRIX

GlobeNewswire

5 months ago

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

NRIX

GlobeNewswire

5 months ago

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

NRIX

Zacks

5 months ago

Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last?

NRIX

MT Newswires

5 months ago

Sanofi Exercises Exclusive License for Nurix Therapeutics' STAT6 Program

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

NRIX

Benzinga

5 months ago

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

NRIX

GlobeNewswire

5 months ago

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

NRIX

GlobeNewswire

6 months ago

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

NRIX

GlobeNewswire

6 months ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

NRIX

GlobeNewswire

6 months ago

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

NRIX

GlobeNewswire

6 months ago

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

NRIX

Insider Monkey

6 months ago

Why Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy Now

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

NRIX

GlobeNewswire

7 months ago

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

NRIX

GlobeNewswire

7 months ago

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

NRIX

MT Newswires

7 months ago

Nurix Says FDA Clears Oral IRAK4 Degrader Application for Inflammatory Diseases; Shares Up Pre-Bell

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

NRIX

GlobeNewswire

7 months ago

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

NRIX

GlobeNewswire

7 months ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NRIX

MT Newswires

7 months ago

UBS Adjusts Price Target on Nurix Therapeutics to $30 From $35, Keeps Buy Rating

Nurix Therapeutics First Quarter 2025 Earnings: Beats Expectations

NRIX

Simply Wall St.

7 months ago

Nurix Therapeutics First Quarter 2025 Earnings: Beats Expectations

NRIX

Zacks

7 months ago

Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates

NRIX

MT Newswires

7 months ago

Nurix Therapeutics Q1 Net Loss Narrows, Revenue Increases

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

NRIX

GlobeNewswire

7 months ago

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

NRIX

Zacks

7 months ago

NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program

NRIX

Zacks

7 months ago

Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

NRIX

MT Newswires

7 months ago

Nurix Therapeutics Signs Exclusive Licensing Deal With Sanofi for Autoimmune Disease Program

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

NRIX

GlobeNewswire

7 months ago

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

NRIX

GlobeNewswire

8 months ago

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

NRIX

MT Newswires

8 months ago

Nurix Therapeutics' Blood Cancer Drug Candidate Gets FDA Orphan Drug Designation

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

NRIX

GlobeNewswire

8 months ago

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

NRIX

GlobeNewswire

8 months ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

NRIX

GlobeNewswire

8 months ago

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

NRIX

Zacks

8 months ago

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

Zymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock?

NRIX

Zacks

8 months ago

Zymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock?

NRIX

GlobeNewswire

8 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

NRIX

GlobeNewswire

9 months ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

NRIX

GlobeNewswire

9 months ago

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

NRIX

MT Newswires

10 months ago

RBC Raises Price Target on Nurix Therapeutics to $27 From $26, Keeps Outperform, Speculative Risk

NRIX

Zacks

10 months ago

Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates

NRIX

MT Newswires

10 months ago

Nurix Therapeutics Fiscal Q4 Net Loss Narrows, Revenue Falls

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

NRIX

GlobeNewswire

10 months ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

NRIX

GlobeNewswire

10 months ago

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

NRIX

Simply Wall St.

10 months ago

We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases

NRIX

GlobeNewswire

10 months ago

Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases

Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?

NRIX

Zacks

10 months ago

Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

NRIX

GlobeNewswire

10 months ago

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

NRIX

MT Newswires

a year ago

Nurix Therapeutics Says Waldenstrom Macroglobulinemia Drug Granted Fast Track Designation by FDA

$Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia$

NRIX

GlobeNewswire

a year ago

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

NRIX

Insider Monkey

a year ago

Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers?

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

NRIX

GlobeNewswire

a year ago

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

NRIX

MT Newswires

a year ago

BMO Capital Initiates Nurix Therapeutics at Outperform With $35 Price Target

NRIX

Insider Monkey

a year ago

Why Is Nurix Therapeutics, Inc. (NRIX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

NRIX

GlobeNewswire

a year ago

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

NRIX

GlobeNewswire

a year ago

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

NRIX

MT Newswires

a year ago

Nurix Therapeutics Gets Priority Medicines Label for NX-5948 in Europe

$Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia$

NRIX

GlobeNewswire

a year ago

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

NRIX

GlobeNewswire

a year ago

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

NRIX

GlobeNewswire

a year ago

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

NRIX

GlobeNewswire

a year ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

NRIX

MT Newswires

a year ago

UBS Initiates Nurix Therapeutics With Buy Rating, $35 Price Target

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

NRIX

GlobeNewswire

a year ago

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trial

NRIX

Clinical Trials Arena

a year ago

Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trial

$Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia$